Treatment‐related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib

Introduction The efficacy of olaparib for treatment‐related neuroendocrine prostate cancer is unknown. Here, we report a case of treatment‐related neuroendocrine prostate cancer with a BRCA2 mutation that was treated with olaparib with 1‐year efficacy. Case presentation A 75‐year‐old man initially d...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Riko Ikeda, Yoh Matsuoka, Masaharu Inoue, Ayataka Ishikawa, Kiwamu Akagi, Yukio Kageyama
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2024-03-01
Serie:	IJU Case Reports
Soggetti:	BRCA2 castration‐resistant neuroendocrine tumor poly(ADP‐ribose) polymerase inhibitors prostate cancer
Accesso online:	https://doi.org/10.1002/iju5.12679
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!